Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KOD Kodiak Sciences	$3.47 -14.5%	$3.29	$1.92 ▼ $11.60	$185.36M	2.42	350,822 shs	320,957 shs
NUVB Nuvation Bio	$2.03 -6.7%	$2.00	$1.54 ▼ $3.97	$692.44M	1.42	2.25 million shs	4.96 million shs
OCS Oculis	$17.80 +1.1%	$17.90	$10.79 ▼ $23.08	$777.18M	0.27	43,465 shs	6,239 shs
XERS Xeris Biopharma	$4.90 -3.6%	$4.74	$1.86 ▼ $6.07	$765.51M	1.1	1.95 million shs	1.19 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KOD Kodiak Sciences	+9.43%	+0.74%	+42.76%	-18.65%	+24.54%
NUVB Nuvation Bio	-6.09%	-1.37%	+9.92%	-6.01%	-38.02%
OCS Oculis	-1.29%	-0.90%	-3.67%	-16.98%	+47.90%
XERS Xeris Biopharma	+4.31%	+3.67%	+23.60%	+27.96%	+147.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KOD Kodiak Sciences	3.7167 of 5 stars	3.0	1.0	4.6	1.7	3.3	0.6
NUVB Nuvation Bio	3.663 of 5 stars	4.6	0.0	0.0	3.4	5.0	0.6
OCS Oculis	2.4701 of 5 stars	3.5	5.0	0.0	1.9	0.0	0.6
XERS Xeris Biopharma	4.6091 of 5 stars	4.4	3.0	4.2	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KOD Kodiak Sciences	2.00	Hold	$9.00	159.37% Upside
NUVB Nuvation Bio	3.17	Buy	$7.83	286.83% Upside
OCS Oculis	3.00	Buy	$31.50	76.97% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	27.68% Upside

Current Analyst Ratings Breakdown

Latest KOD, NUVB, OCS, and XERS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00
5/9/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
4/23/2025	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$6.00
4/23/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$6.00
4/17/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $32.00
4/17/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/31/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/27/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/13/2025	OCS Oculis	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$37.00 ➝ $41.00

(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$5.07 per share	N/A
NUVB Nuvation Bio	$10.96M	62.89	N/A	N/A	$2.76 per share	0.73
OCS Oculis	$980K	793.04	N/A	N/A	$2.87 per share	6.20
XERS Xeris Biopharma	$222.55M	3.44	N/A	N/A	($0.05) per share	-97.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KOD Kodiak Sciences	-$260.49M	-$3.63	N/A	N/A	N/A	N/A	-84.52%	-45.40%	5/21/2025 (Estimated)
NUVB Nuvation Bio	-$75.80M	-$2.35	N/A	N/A	N/A	N/A	-21.89%	-17.86%	8/4/2025 (Estimated)
OCS Oculis	-$98.92M	-$2.64	N/A	N/A	N/A	-8,043.28%	-71.31%	-56.85%	N/A
XERS Xeris Biopharma	-$62.26M	-$0.30	N/A	N/A	N/A	-33.69%	N/A	-17.38%	N/A

Latest KOD, NUVB, OCS, and XERS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/8/2025	Q1 2025	OCS Oculis	-$0.51	-$0.77	-$0.26	-$0.77	$0.22 million	$0.32 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A
3/11/2025	Q4 2024	OCS Oculis	-$0.48	-$0.76	-$0.28	-$0.76	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KOD Kodiak Sciences	N/A	8.42	8.42
NUVB Nuvation Bio	N/A	9.57	9.57
OCS Oculis	0.01	4.02	4.02
XERS Xeris Biopharma	N/A	1.79	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KOD Kodiak Sciences	89.06%
NUVB Nuvation Bio	61.67%
OCS Oculis	22.30%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
KOD Kodiak Sciences	45.30%
NUVB Nuvation Bio	29.93%
OCS Oculis	N/A
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KOD Kodiak Sciences	90	52.76 million	28.79 million	Optionable
NUVB Nuvation Bio	60	340.26 million	319.50 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable
XERS Xeris Biopharma	290	156.39 million	142.28 million	Optionable

KOD, NUVB, OCS, and XERS Headlines

Recent News About These Companies

Xeris Announces Details for Analyst & Investor Day

May 20 at 8:10 AM | businesswire.com

Stonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 20 at 7:02 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.

May 20 at 4:20 AM | marketbeat.com

Leerink Partnrs Weighs in on Xeris Biopharma Q2 Earnings

May 17, 2025 | marketbeat.com

Leerink Partnrs Forecasts Xeris Biopharma Q2 Earnings

May 17, 2025 | americanbankingnews.com

Parkman Healthcare Partners LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 16, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Lowers Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 13, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Driehaus Capital Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 12, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Given New $7.00 Price Target at Oppenheimer

May 11, 2025 | americanbankingnews.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Tudor Investment Corp ET AL Reduces Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 9, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

4XERS : Earnings Outlook For Xeris Biopharma Holdings

May 7, 2025 | benzinga.com

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Reduced by Caxton Corp

May 7, 2025 | marketbeat.com

Xeris Biopharma (XERS) Projected to Post Earnings on Thursday

May 3, 2025 | marketbeat.com

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, NUVB, OCS, and XERS Company Descriptions

Kodiak Sciences NASDAQ:KOD

$3.47 -0.59 (-14.53%)

As of 02:01 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Nuvation Bio NYSE:NUVB

$2.02 -0.15 (-6.68%)

As of 02:01 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Oculis NASDAQ:OCS

$17.80 +0.20 (+1.14%)

As of 01:56 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Xeris Biopharma NASDAQ:XERS

$4.89 -0.19 (-3.64%)

As of 02:01 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time